La tétracycline, connue sous le nom commercial Sumycin, agit en bloquant la fixation de l’ARNt sur la sous-unité 30S ribosomale, interrompant l’élongation de la chaîne protéique bactérienne. Ce mécanisme confère une activité sur un spectre large, incluant bactéries Gram positives, Gram négatives, rickettsies et spirochètes. Sa biodisponibilité digestive varie selon la prise alimentaire et les interactions avec les ions divalents comme calcium et magnésium. Sa diffusion tissulaire est importante, notamment dans les voies respiratoires et génito-urinaires. L’élimination se fait par voie rénale et biliaire. Les effets indésirables incluent photosensibilisation, troubles digestifs et coloration dentaire en cas d’administration précoce. Les guides thérapeutiques mentionnent sumycin prix, en soulignant la nécessité de restreindre son utilisation afin de limiter les résistances acquises.
腎功能不全時應監測濃度,調整藥物劑量(但常被忽略)之藥物
腎功能不全時應監測濃度,調整藥物劑量(但常被忽略)之藥物
項次 藥物
ClCr <15 ml/min--2 mg on dailysis day
<3 mg/min: 100 mg at extended intervals
<10 ml/min-- in fast acetylators Q8-16H
ClCr 30-50: 0.25 mg QD or 0.5 mg QOD (treatment-naive)
ClCr <10: 0.05 mg QD or 0.5 Q7D (treatment-naive)
10-50 ml/min Q6-12H; <10 ml/min Q12-18H
Clcr<25 ml/min:dosage adjustments may be necessary
Clcr<25 ml/min:dosage adjustments may be necessary
1# QD in moderate renal impairment and in patients on
10-50 ml/min 75%; <10 ml/min 50% of the usual dose
10-50 ml/min <0.6 mg/day to every other day
ClCr<30 ml/min not on hemodialysis: starting dose should
be 5 milligrams (mg) once daily with titration not to
lower dose and then increased gradually; not
recommended for patients with end-stage renal disease
(requiring dialysis) or severe renal impairment (ClCr<30
GFR 10 to 50 ml/min: 75% of the usual dose
GFR <10 ml/min: 50% of the usual dose
GFR >50 ml/min Q6H; 10-50 ml/min Q12H; <10 ml/min
Clcr 5-29 ml/min: 5 mg ORALLY twice daily
GFR 10 to 50 ml/min: Q24-36H; <10 ml/min Q48H
GFR 10-70 ml/min: 75%; hemodialysis: 50%
GFR 10-70 ml/min: 75%; hemodialysis: 50%
Initial dose should be 50 mg QD in renal impairment
Initial dose should be 50 mg QD in renal impairment
Thiazides should not be used in patients with a serum
creatinine or urea nitrogen level greater than 2.5 mg/Dl
GFR <10 ml/min: 50%; 10-50 ml/min: 75%
GFR 10 to 50 ml/mi: 75% ; <10 ml/min 50%
Clcr<25 ml/min:dosage adjustments may be necessary
Contraindicated in advanced renal impairment
Adjustment for patients with a ClCr< 20 mL/minute
<30 ml/min halved or the dosing interval doubled
GFR 10 to 50 ml/min: 50 to 75%; <10 ml/min: 25 to 50%
Initial dose should be 50 mg QD in renal impairment
GFR 10 to 50 ml/min: 50%; <10 ml/min: 25%
Initial dose should be 50 mg QD in renal impairment
GFR10-50 ml/min: 50%; <10 ml/min: avoided
The lower dose of 7.5 milligrams daily has been suggested
GFR10-50 ml/min: 75%; <10 ml/min: 50%
A reduction in daily dosage should be considered (Clcr<20
A reduction in daily dosage should be considered (Clcr<20
GFR> 50 ml/min: Q6H; 10 to 50 ml/min: Q12-18H;
Potential need for dose adjustments in renal insufficiency
Clcr 10 to 30 mL/min: 5 mg/day; < 10 mL/min: 2.5mg/day
CrCl 20 to 40 ml/min: starting dose 0.5 mg
ClCr>60 ml/min--4 mg/day; 30-60 ml/min--2 mg/day;
15-30 ml/min--2 mg/QOD; <15 ml/min--2 mg on dailysis
GFR <10 ml/min: 50%; 10-50 ml/min: 75%
Clcr<25 ml/min:dosage adjustments may be necessary
< 40 ml/min (>2.5 mg/dL), oral dosing should be reduced
Moderate: < 16 mg/day; severe (creatinine clearance < 9
Patients in renal failure may require higher than usual
Dosage of sulfonamides be adjusted in patients with
Serum creatinine is recommended to be maintained less
ClCr 30 to 49 mL/min: 600 mg QOD; <30 mL/min: 600
mg Q72H; ESRD requiring hemodialysis: 600 mg Q96H,
Clcr<50 ml/min: 50%; Clcr<25 ml/min: 25%
> 50 mL/min Q6-12H; 10 to 50 mL/min Q12-24; <10
112 Superocin(Ciprofloxacin)250 mg 30-50 ml/min 250-500 mg Q12H; 5-29 ml/min 250-500
Slight reduction in the normal dose or by increasing the
Clcr10-30 ml/min:treatment--75 mg/day; prophylaxis--75
> 50 ml/min Q8-12H; 10 to 50 ml/min Q12-24H; < 10
ml/min Q24H, but is best avoided in these patients
One half of the usual adult dose is recommended
Do not use extended-release tramadol in patients with
severe renal impairment (creatinine clearance less than 30
< 30 ml/min: initiated at 300mg/day, one-half the usual
starting dose, and increased at a slower rate than usual
Clcr<30 ml/min: 25 mg (starting dose)
Clcr 10 to 30 mL/min: 5 mg/day; < 10 mL/min: 2.5mg/day
Eur J Clin Pharmacol (2011) 67:701–707DOI 10.1007/s00228-011-0994-7Effects of SLCO1B1 polymorphisms on the pharmacokineticsand pharmacodynamics of repaglinide in healthy ChinesevolunteersJiake He & Zhixia Qiu & Ning Li & Yang Yu & Yang Lu & Deen Han & Tingting Li &Di Zhao & Wei Sun & Fang Fang & Jianheng Zheng & Hongwei Fan & Xijing ChenReceived
Reglamento de la Denominación de Origen «Roncal» CAPÍTULO PRIMERO Artículo 1. De acuerdo con lo dispuesto en la Ley 25/1970, de 2 de diciembre, y en su Reglamento, aprobado por Decreto 835/1972, de 23 de marzo, en el Decreto 3711/1974, de 20 de diciembre, en el Real Decreto 728/1988, de 8 de julio y en el Real Decreto 2654/1985, de 18 de diciembre, de traspaso de funciones y servicio